Genesis announced the completion of a $21 million round B financing
-
Last Update: 2021-03-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
yesterday, Genesis announced the completion of a $21m round of B financing, led by Vertex Ventures China, Panacea Ventures, Kunlun Capital and China Southern Ventures. It has successfully financed more than US$40 million and will be used primarily to promote clinical research, independent research and development and product introduction worldwide.Genesis has introduced overseas clinical products to China and partnered with overseas partners in global multi-center clinical trials, while developing best-in-class drugs and has launched innovative drug projects for four targets. The currently-created IL-17 drug candidate, IMG-020, is about to enter a globally registered clinical trial for multiple adaptations. (U.S. News Agency)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
